Always Searching


The search for answers to develop an effective medicine can be a long journey. Medical breakthroughs do not happen overnight. They are the product of

years of careful research. We here at BMS are dedicated to researching different types of options for lung cancer and are committed to keeping up the search.

years of careful research. We here at BMS are dedicated to researching different types of options for lung cancer and are committed to keeping up the search.

The Building Blocks

Here are some treatments you may already be familiar with. These options are the foundational choices for lung cancer. They may be used alone or in combination with other options.

Surgery

This treatment is used most commonly when cancer is in its early stages and depends largely on the stage and size of tumors

Radiation

This treatment uses high-energy rays and depends largely on the stage and size of tumors

Chemotherapy

This treatment uses drugs to stop the growth of cancer cells

Targeted Therapy

This treatment targets cancer's specific genes, proteins, or the tissue environment that contributes to cancer growth and survival

Immunotherapy

This treatment targets your body’s immune system

Combination Treatments

While monotherapy treatments are continuing to be researched,
combination treatments are also increasingly playing a larger role in treating lung cancer. Many of these combinations include immunotherapy. These are not all the options Bristol Myers Squibb is researching, and, as we move ahead, more options may be added or combined. Like any scientific research, there are no guaranteed results.

Immunotherapy + Immunotherapy

This treatment combines 2 or more different types of immunotherapies

We are looking at multiple immunotherapy options in our research

Immunotherapy + Immunotherapy

This treatment combines 2 or more different types of immunotherapies

We are looking at multiple immunotherapy options in our research

Immunotherapy + Chemotherapy

This treatment combines immunotherapy with chemotherapy

Immunotherapy + Chemotherapy

This treatment combines immunotherapy with chemotherapy

Immunotherapy + Radiation

This treatment combines high-energy rays and immunotherapies

Immunotherapy + Radiation

This treatment combines high-energy rays and immunotherapies

Immunotherapy + Immunotherapy + Chemotherapy

This treatment combines 2 different types of immunotherapies and chemotherapy

Immunotherapy + Immunotherapy + Chemotherapy

This treatment combines 2 different types of immunotherapies and chemotherapy

Immunotherapy + Radiation +
Targeted Therapy

This treatment combines immunotherapy with radiation and a targeted therapy

Immunotherapy + Radiation +
Targeted Therapy

This treatment combines immunotherapy with radiation and a targeted therapy

Immunotherapy + Immunotherapy + Targeted Therapy

This treatment combines 2 different types of immunotherapy and a targeted therapy

Immunotherapy + Immunotherapy + Targeted Therapy

This treatment combines 2 different types of immunotherapy and a targeted therapy

Immunotherapy + Chemotherapy + Targeted Therapy

This treatment combines immunotherapy, chemotherapy, and a targeted therapy

Immunotherapy + Chemotherapy + Targeted Therapy

This treatment combines immunotherapy, chemotherapy, and a targeted therapy

More research is happening with immunotherapy-based monotherapy and combination options in lung cancer, and we continue to move forward. Research can be complicated and takes a lot of time, but that won’t stop

Bristol Myers Squibb on our search for the next option. But then that’s the BMS promise:
Always Searching
.

The safety and efficacy of investigational agents and/or investigational uses have not been established.

Bristol Myers Squibb on our search for the next option. But then that’s the BMS promise: Always Searching.

The safety and efficacy of investigational agents and/or investigational uses have not been established.

Stay connected for news about the latest advances in treating lung cancer from BMS.

It’s incredibly motivating to consider how the scientific questions we are addressing today will lead to new options and approaches for future generations.


TIMOTHY REILLY,

Senior Vice President and Head of Early Development Program Leadership

 
 

Making Strides


Discovery is in our DNA. At Bristol Myers Squibb, we aren’t just researchers and doctors. Some of us are caregivers or even patients.

While BMS is focused on progressing research, we learn from history. Our aim in the past was the same as it is for the future—doing what we can to help all

of our patients live longer. The progress we’ve made shows that medical advances take time—in our case, decades of research and development. The achievements of our past combined with today’s research are what we hope will make the next breakthrough possible.

of our patients live longer. The progress we’ve made shows that medical advances take time—in our case, decades of research and development. The achievements of our past combined with today’s research are what we hope will make the next breakthrough possible.

1967

BMS research leads to first available chemotherapy treatment

2004

BMS research leads to first available targeted therapy treatment

2005

BMS research leads to first available immunomodulatory therapy treatment

2011

BMS research leads to first available immune checkpoint inhibitor treatment

2020

What will happen as BMS begins this decade? Stay informed: connect with us to find out more

1967

2004

2005

2011

2020

Stay connected for news about the latest advances in treating lung cancer from BMS.

One of the best parts of being a researcher is knowing our work may directly benefit patients. They are more than just numbers and statistics, they are lives we hope to positively impact.


MICHAELA BOWDEN,

Executive Director Solid Tumor Disease Team, Translational Medicine

Staying Connected


Bristol Myers Squibb is proud of its past accomplishments. But we don’t plan on stopping. Stay connected for news about the latest advances in treating lung cancer from BMS.

Loading...